Evidence map›Paper›PMID 38494192›Full record

ArticleInfluenza and other respiratory viruses2024

Risk of COVID-19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders.

Matthew E Levy, Duck-Hye Yang, Margaret M Dunne, Kathleen Miley, Stephanie A Irving, Shaun J Grannis, Zachary A Weber, Eric P Griggs, Talia L Spark, Elizabeth Bassett and 30 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors at 13 institutions in 1 country.

Matthew E LevyWestat, Rockville, Maryland, USA.ORCID 0000-0002-2164-1726
Duck-Hye YangWestat, Rockville, Maryland, USA.
Margaret M DunneWestat, Rockville, Maryland, USA.
Kathleen MileyHealthPartners Institute, Minneapolis, Minnesota, USA.
Stephanie A IrvingKaiser Permanente Center for Health Research, Portland, Oregon, USA.
Shaun J GrannisCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
Zachary A WeberWestat, Rockville, Maryland, USA.
Eric P GriggsCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Talia L SparkWestat, Rockville, Maryland, USA.
Elizabeth BassettWestat, Rockville, Maryland, USA.
Peter J EmbiCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
Manjusha GaglaniBaylor Scott & White Health, Temple, Texas, USA.
Karthik NatarajanDepartment of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.
Nimish R ValviCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
Toan C OngSchool of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Allison L NalewayKaiser Permanente Center for Health Research, Portland, Oregon, USA.
Edward StenehjemDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
Nicola P KleinKaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, USA.
Ruth Link-GellesCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Malini B DeSilvaHealthPartners Institute, Minneapolis, Minnesota, USA.
Anupam B KharbandaChildren's Minnesota, Minneapolis, Minnesota, USA.
Chandni RaiyaniBaylor Scott & White Health, Temple, Texas, USA.
Maura A BeatonDepartment of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.
Brian E DixonCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
Suchitra RaoSchool of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-0334-6301
Kristin DascombDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
Palak PatelInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Mufaddal MamawalaBaylor Scott & White Health, Temple, Texas, USA.
Jungmi HanDepartment of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.
William F FadelCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
Michelle A BarronSchool of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Nancy GriselDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
Monica DickersonInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
I-Chia LiaoBaylor Scott & White Health, Temple, Texas, USA.
Julie ArndorferDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
Morgan NajdowskiCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Kempapura MurthyBaylor Scott & White Health, Temple, Texas, USA.
Caitlin RayInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Mark W TenfordeInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Sarah W BallWestat, Rockville, Maryland, USA.
Centers for Disease Control and Prevention · USWestat (United States) · USIntermountain Healthcare · USRegenstrief Institute · USUniversity of Colorado Anschutz Medical Campus · USColumbia University Irving Medical Center · USHealthPartners · USIndiana University Health · USKaiser Permanente Center for Health Research · USChildren's Minnesota · USKaiser Permanente · USNewYork–Presbyterian Hospital · USTemple College · US

Funding

CDC HHS 75D30120C07986
6 · The paper itself

Abstract

backgroundAlthough psychiatric disorders have been associated with reduced immune responses to other vaccines, it remains unknown whether they influence COVID-19 vaccine effectiveness (VE). This study evaluated risk of COVID-19 hospitalization and estimated mRNA VE stratified by psychiatric disorder status.

methodsIn a retrospective cohort analysis of the VISION Network in four US states, the rate of laboratory-confirmed COVID-19-associated hospitalization between December 2021 and August 2022 was compared across psychiatric diagnoses and by monovalent mRNA COVID-19 vaccination status using Cox proportional hazards regression.

resultsAmong 2,436,999 adults, 22.1% had ≥1 psychiatric disorder. The incidence of COVID-19-associated hospitalization was higher among patients with any versus no psychiatric disorder (394 vs. 156 per 100,000 person-years, p < 0.001). Any psychiatric disorder (adjusted hazard ratio [aHR], 1.27; 95% CI, 1.18-1.37) and mood (aHR, 1.25; 95% CI, 1.15-1.36), anxiety (aHR, 1.33, 95% CI, 1.22-1.45), and psychotic (aHR, 1.41; 95% CI, 1.14-1.74) disorders were each significant independent predictors of hospitalization. Among patients with any psychiatric disorder, aHRs for the association between vaccination and hospitalization were 0.35 (95% CI, 0.25-0.49) after a recent second dose, 0.08 (95% CI, 0.06-0.11) after a recent third dose, and 0.33 (95% CI, 0.17-0.66) after a recent fourth dose, compared to unvaccinated patients. Corresponding VE estimates were 65%, 92%, and 67%, respectively, and were similar among patients with no psychiatric disorder (68%, 92%, and 79%).

conclusionPsychiatric disorders were associated with increased risk of COVID-19-associated hospitalization. However, mRNA vaccination provided similar protection regardless of psychiatric disorder status, highlighting its benefit for individuals with psychiatric disorders.

Indexed as

COVID-19Mental DisordersAdultCOVID-19 VaccinesHospitalizationHumansRetrospective StudiesRNA, MessengerVaccinationCOVID-19 VaccinesRNA, Messengeranxiety disordersCOVID-19electronic health recordsepidemiologymental disordersmood disorderspsychotic disordersvaccination

Identifiers

PMID38494192
PMCPMC10944689
OpenAlexW4393097759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.